Sandoz Eyes In-House GLP-1 Development – Apart From ‘Key’ APIs

Device Manufacture And Fill-Finish Part Of Internal Capabilities

 
• By Dean Rudge

With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.

Digital money send, currency exchange sign. Neon futuristic transfer arrow icon. Web trade symbol. Mutual exchange of information isolated on blue background
Sandoz will use both its in-house capabilities and partnerships • Source: Shutterstock

More from Archive

More from Generics Bulletin